Ontvang nu dagelijks onze kooptips!

word abonnee
Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert
Home  /   Forum   /   Crucell   /   RT vrijdag 1 december 2006

Crucell« Terug naar discussie overzicht

RT vrijdag 1 december 2006

Volgen
362 Posts
Pagina: 1 2 3 4 5 6 ... 19 »» | Laatste | Omlaag ↓
  1. [verwijderd] 1 december 2006 05:39
    Beste Forumgenoten,

    Vrijdag 1 december 2006, gaat het de dag worden om nooit te vergeten of om snel te vergeten? Nog een paar uur en dan gaan we het weten.

    Deze week (nog) geen officieel Crucell-nieuws. Wel een paar mooie verhalen over "ons" Crucell waaronder van IRIS die het uitlichten waard zijn:

    Grolsch, Crucell en TomTom aangemerkt als parels
    tinyurl.com/ursqp

    Ook zet IRIS Crucell al een tijdje in de top 5 met een positieve "fair value" van >50%
    tradersonline.irisresearch.nl/idphome...

    Genoeg gepraat, tijd voor waar het echt om draait. De harde cijfers van deze week:

    Vrijdag 18,13
    Maandag 17,84
    Dinsdag 17,53
    Woensdag 18,21
    Donderdag 18,19 -0,02 (-0,11%)
    - Open 18,28
    - Hoog 18,41
    - Laag 18,03
    - Omzet 785.978

    Donderdag USA 24,12 +0,21 (+0,88%)
    Omzet 118.526

    Nu we 3 maanden verder zijn weer aangeland rond de koers van vrijdag 22 september (18,21) is het tijd wellicht nu de dag om de koers weer een flinke impuls te geven.

    Marcel Wijma, voor U de dag om op uw bek te gaan en hem voorlopig te houden of (hopelijk) toch die dag om voorlopig niet te vergeten!

    Rest mij u allen een Crucellig weekend te wensen en een fijne (handels-)dag!
  5. [verwijderd] 1 december 2006 08:06

    PRESS RELEASE

    Crucell Awarded Contracts of Over $230 Million for Quinvaxem(TM) and Hepavax-Gene® Vaccines

    Leiden, The Netherlands, December 1, 2006 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) announced today that it has been awarded contracts totaling over US $230 million for its Quinvaxem(TM) and Hepavax-Gene® paediatric vaccines by supranational organizations. The contracts cover the next three years until 2009, with the awarded amount growing over those three years.

    Following the WHO prequalification in September 2006 the combination vaccine was made available to supranational purchasing organizations. Supranational organizations are major customers for combination vaccines, which are used in large vaccination programs in developing countries.

    Quinvaxem(TM), a fully-liquid pentavalent vaccine for children, was co-developed with Novartis Vaccines and Diagnostics and is produced in Crucell's laboratories in South Korea. The vaccine combines antigens for protection against five important childhood diseases: diphtheria, tetanus, pertussis (whooping cough), hepatitis B and Haemophilus influenzae type b, one of the leading causes of bacterial meningitis and pneumonia in children.

    Current demand for the Quinvaxem® vaccine exceeds 50 million doses. The total market potential is 150 million doses per year in 3 to 4 years.

    The Hepavax-Gene®, recombinant hepatitis B vaccine, is one of the WHO's pre-qualified vaccines for active immunization against the hepatitis B virus. Young children infected with HBV are the most likely to develop chronic infections. Hepavax-Gene® was internationally introduced in 1996 and has become one of today's major hepatitis B vaccines supplied to more than 90 countries.

    "The multiple year contracts that the supranational organizations have granted to Crucell, underline Crucell's position as a leading supplier of important vaccines. Quinvaxem(TM) is the first internationally available fully-liquid vaccine containing these five life saving antigens and it will make a significant contribution to children's vaccination programs in the developing world," stated Crucell's CEO, Dr Ronald H.P. Brus. "Quinvaxem(TM) will be an important contributor to the Company's 2006 total revenues, estimated between EUR 140 million - EUR 150 million and its aim to achieve cash break-even in 2007."

    About Crucell
    Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) is a biotechnology company focused on research, development and worldwide marketing of vaccines and antibodies that prevent and treat infectious diseases. Its vaccines are sold in public and private markets worldwide. Crucell's core portfolio includes a vaccine against hepatitis B, a fully-liquid vaccine against five important childhood diseases, and a virosome-adjuvanted vaccine against influenza. Crucell also markets travel vaccines, such as the only oral anti-typhoid vaccine, an oral cholera vaccine and the only aluminum-free hepatitis A vaccine on the market. The Company has a broad development pipeline, with several Crucell products based on its unique PER.C6® production technology. The Company licenses this and other technologies to the biopharmaceutical industry. Important partners and licensees include DSM Biologics, sanofi aventis, GSK and Merck & Co. Crucell is headquartered in Leiden (the Netherlands), with subsidiaries in Switzerland, Spain, Italy, Korea and the US. The Company employs about 900 people. For more information, please visit www.crucell.com.

    Forward-looking statements
    This press release contains forward-looking statements that involve inherent risks and uncertainties. We have identified certain important factors that may cause actual results to differ materially from those contained in such forward-looking statements. For information relating to these factors please refer to our Form 20-F, as filed with the U.S. Securities and Exchange Commission on July 6, 2006, and the section entitled "Risk Factors". The Company prepares its financial statements under generally accepted accounting principles in the United States (US GAAP) and Europe (IFRS).

    For further information please contact:

    Crucell N.V.
    Leonard Kruimer
    Chief Financial Officer
    Tel. +31 (0)71 524 8722
    l.kruimer@crucell.com

    Paul Vermeij
    Director Investor Relations and Corporate Communications
    Tel. +31 (0)71 524 8718
    p.vermeij@crucell.com

    For Crucell in the US:
    Redington, Inc.
    Thomas Redington
    Tel. +1 212-926-1733
    tredington@redingtoninc.com

    PDF file

    For more information about Crucell, please visit our website: www.crucell.com

    If you no longer wish to receive Crucell news, you can unsubcribe via the following link: cws.huginonline.com/C/132631/unsubscr...

    --------------------------------------------------------------------------------

    This content was distributed through



    - connecting communication professionals with their target audience. Visit us here.
    Unsubscribe
  13. [verwijderd] 1 december 2006 08:14
    En toch valt het bedrag me tegen. Maar ze kunnen allicht nog wat bijbestellen. Ik vraag me zelfs af of de productiecapaciteit hiermee volledig is bezet (voor Q dan). Maar er zijn ook nog andere afnemers.
    60 mio in euro's per jaar is een mooie bodem zullen we maar zeggen.
    Maar of het genoeg is hoor ik graag van anderen.
  17. [verwijderd] 1 december 2006 08:17
    Orderboek Bieden Laten
    Tijd Aantal Koers Koers Aantal Tijd
    01-12 08:01 1.250 AT BEST AT BEST 550 01-12 08:01
    01-12 08:01 90 18,38 18,38 1.500 01-12 08:01
    01-12 08:01 509 18,30 18,39 1.000 01-12 08:01
    01-12 08:01 150 18,25 18,40 1.150 01-12 08:01
    01-12 08:01 120 18,22 18,42 300 01-12 08:01
362 Posts
Pagina: 1 2 3 4 5 6 ... 19 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Markt Vandaag

Stijgers

instrument koers absoluut verschil relatief verschil
Air France-KLM 8,020 +0,32 +4,18%
HEIJMANS KON 31,550 +1,20 +3,95%
ASML 706,700 +24,20 +3,55%
Aperam 27,120 +0,88 +3,35%
UMG 27,030 +0,84 +3,21%
ADYEN NV 1.563,000 +47,00 +3,10%
ASMI 547,000 +15,80 +2,97%
SHELL PLC 32,005 +0,91 +2,91%
ALLFUNDS GROUP 5,110 +0,14 +2,82%
Alfen N.V. 14,465 +0,39 +2,73%
FASTNED 21,050 +0,55 +2,68%
PostNL 0,985 +0,02 +2,55%
OCI 11,380 +0,28 +2,52%
Philips Koninklijke 26,860 +0,65 +2,48%
Arcadis 55,350 +1,20 +2,22%
Kendrion 10,400 +0,22 +2,16%
Brunel 9,470 +0,20 +2,16%
Fugro 15,450 +0,32 +2,12%
Nedap N.V. 59,600 +1,20 +2,05%
ArcelorMittal 24,270 +0,48 +2,02%
CTP 16,180 +0,30 +1,89%
EXOR NV 91,550 +1,60 +1,78%
Sif Holding 11,960 +0,20 +1,70%
AEX 919,00 +14,06 +1,55%
TKH 35,360 +0,54 +1,55%
RELX 48,080 +0,72 +1,52%
ACOMO 18,100 +0,26 +1,46%
NSI 21,450 +0,30 +1,42%
Eurocommercial Properties 23,300 +0,30 +1,30%
ASCX 1.266,31 +14,75 +1,18%
WDP 20,680 +0,24 +1,17%
Pharming 0,865 +0,01 +1,17%
Wereldhave 14,540 +0,16 +1,11%
AMX 844,19 +8,87 +1,06%
Wolters Kluwer 175,050 +1,70 +0,98%
Corbion 23,020 +0,22 +0,96%
UNILEVER PLC 55,720 +0,50 +0,91%
Fagron 19,160 +0,16 +0,84%
AALBERTS NV 34,400 +0,26 +0,76%
B&S Group SA 4,200 +0,03 +0,72%
NX FILTRATION 2,900 +0,02 +0,69%
IMCD 151,100 +0,90 +0,60%
Flow Traders 23,720 +0,14 +0,59%
BAM 4,114 +0,02 +0,54%
PROSUS 36,655 +0,20 +0,53%
CM.COM 5,790 +0,03 +0,52%
Heineken 67,520 +0,34 +0,51%
Basic-Fit 24,480 +0,12 +0,49%
BESI 122,900 +0,60 +0,49%
JDE PEET'S 16,840 +0,08 +0,48%
JUST EAT TAKEAWAY 11,760 +0,05 +0,47%
Ahold Delhaize 34,380 +0,16 +0,47%
Van Lanschot Kempen NV 47,500 +0,20 +0,42%
RENEWI 9,580 +0,04 +0,42%
Sligro 10,720 +0,04 +0,37%
Vopak 43,180 +0,16 +0,37%
ABN AMRO BANK N.V. 16,365 +0,05 +0,31%
ForFarmers 3,360 +0,01 +0,30%
Accsys 0,550 +0,00 +0,18%
Avantium 1,736 +0,00 +0,12%
ING 16,150 +0,01 +0,07%
INPOST 15,860 0,00 0,00%
TomTom 5,220 0,00 0,00%

Dalers

instrument koers absoluut verschil relatief verschil
KPN 3,554 -0,07 -1,88%
DSM FIRMENICH AG 98,380 -1,42 -1,42%
VASTNED 28,400 -0,40 -1,39%
RANDSTAD NV 41,740 -0,53 -1,25%
THEON INTERNAT 13,300 -0,16 -1,19%
Akzo Nobel 56,340 -0,58 -1,02%
Aegon 6,316 -0,06 -0,88%
ASR Nederland 47,700 -0,34 -0,71%
AZERION 1,590 -0,01 -0,63%
SBM Offshore 17,690 -0,10 -0,56%
EBUSCO HOLDING 0,917 0,00 -0,52%
SIGNIFY NV 21,100 -0,08 -0,38%
NN Group 44,260 -0,15 -0,34%
AMG Critical Materials N.V. 13,960 -0,03 -0,21%
Galapagos 22,180 -0,04 -0,18%
vlag naam koers verschil relatief verschil
AEX 919,00 +14,06 +1,55%
AEX GR 3.604,61 +55,14 +1,55%
Germany40^ 21.728,30 +90,77 +0,42%
FTSE 100 8.646,88 +89,07 +1,04%
Europe50^ 5.285,91 +55,25 +1,06%
US30^ 44.885,30 +160,20 +0,36%
Nasd100^ 21.508,10 +68,10 +0,32%
US500^ 6.070,73 +28,59 +0,47%
Japan225^ 39.582,10 +309,90 +0,79%
VD-NEW 14,74 -0,80 -5,14%
#/^ Index indications calculated real time, zie disclaimer